A Phase III, Multicentre, Randomized, Double-blind, Single-Dose, 2-Arm, 2-Period, Crossover Study to Investigate the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (BREATH)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Budesonide/salbutamol (Primary)
- Indications Exercise-induced asthma
- Focus Registrational; Therapeutic Use
- Acronyms BREATH
- Sponsors AstraZeneca
- 26 Jul 2024 Status changed from recruiting to completed.
- 12 Feb 2024 New trial record